Status:
RECRUITING
Tegoprazan and Amoxicillin Dual Therapy
Lead Sponsor:
Soonchunhyang University Hospital
Conditions:
H.Pylori Infection
Eligibility:
All Genders
20-80 years
Brief Summary
Dual therapy for Helicobacter pylori refers to a treatment regimen that combines two agents: a potent acid suppressor (such as a proton pump inhibitor \[PPI\] or a potassium-competitive acid blocker \...
Detailed Description
The investigators aim to evaluate the H. pylori eradication success rate and treatment compliance of tegoprazan and amoxicillin dual therapy.
Eligibility Criteria
Inclusion
- Gastroscopy can be performed
- H. pylori test and pathological analysis can be performed
Exclusion
- Age \< 20 or \> 80 years
- Anemia (serum hemoglobin level \< 10 g/dL)
- Severe systemic disease
- Advanced chronic liver disease
- Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics
- History of H. pylori eradication
- Drug allergy to antibiotics
- History of gastric surgery
- Recent history of upper gastrointestinal bleeding
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06950489
Start Date
January 1 2025
End Date
December 31 2025
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Digestive Disease Center, Soonchunhyang University Hospital
Seoul, South Korea, 04401